Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
The 100 surgeries conducted using robotic technology span various intricate procedures in the fields of Urology, Liver Transplantation, GI surgery, Cardiac surgeries and Gynaecology
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Six engaging sessions focusing on Prevention of Kidney Diseases, Brain Stem Death Declaration, Deceased Donor Management, Prevention of Liver Diseases, Legal Aspects of Organ and Tissue Donation, Eye Donation and Corneal Transplant held as part of the Webinar
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Organ Transplants triple across the country; rise from 5000 (2013) to more than 15000 in 2022
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Subscribe To Our Newsletter & Stay Updated
